T-cells in lupus patients avoid apoptosis and are stimulated to produce antibodies against the patients own DNA

Researchers studying autoimmune diseases have found a molecular mechanism that explains how T-cells in lupus patients avoid apoptosis and are stimulated to produce antibodies against the patients own DNA.

Investigators at Northwestern University (Chicago, IL, USA) used gene microarray profiling, which was validated by functional and biochemical studies, to establish that lupus patients activated T-cells resisted apoptosis by markedly upregulating and sustaining cyclo-oxygenase-2 (COX-2) expression. COX-2 is an enzyme that makes prostaglandins, which cause inflammation, pain, and fever.

Inhibition of COX-2 activity caused apoptosis of lupus T-cells by augmenting Fas signaling and markedly decreasing the survival molecule c-FLIP (cellular homolog of viral FLICE inhibitory protein). Only some COX-2 inhibitors were able to suppress the production of pathogenic autoantibodies to DNA by causing autoimmune T-cell apoptosis, an effect that was independent of prostaglandin E2 (PGE2). These findings were published in the April 2004 issue of Nature Medicine.

Senior author Dr. Syamal Datta, professor of medicine and immunology at Northwestern University said, COX-2 inhibitors also have been used, with limited success, to treat patients with lupus and in laboratory models of lupus, but in doses much lower than the concentration required to achieve cell death and elimination of autoimmune T-cells.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024